<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721264</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-NASH-03</org_study_id>
    <nct_id>NCT02721264</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.</brief_title>
  <official_title>Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological
      evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at
      Institute of Liver and Biliary Sciences, who meet the inclusion criteria and who provide
      informed consent will be included in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Hepatic Venous Pressure Gradient in the two groups from baseline.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver function test as compared to baseline.</measure>
    <time_frame>1 year</time_frame>
    <description>Improvement is defined as Serum bilirubin,AST,ALT,serum Albumin within normal limits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Liver Stiffness Measurement as compared to baseline.</measure>
    <time_frame>1 year</time_frame>
    <description>LSM &lt; 10 Kpa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess improvement in insulin resistance (Fasting plasma and insulin levels, HOMA-IR)</measure>
    <time_frame>1 year</time_frame>
    <description>HOMA IR &lt;2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new onset upper gastrointestinal bleed in both groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of new onset of ascites in both groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Spontaneous Bacterial peritonitis cases in both groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACLF (Acute on Chronic Liver failure) cases in both groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in hepatic and systemic inflammatory markers like TNF-α in both groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in hepatic and systemic inflammatory markers like C Reactive Protein in both groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in hepatic and systemic inflammatory markers like serum endotoxins in both groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological and permeability changes in the duodenal biopsy in both groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation (FMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant</intervention_name>
    <arm_group_label>Fecal Microbiota Transplantation (FMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <arm_group_label>Standard Treatment Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age more then 18 years.

          2. All patients with cirrhosis with current or previous histological evidence of
             steatosis or steatohepatitis.

          3. Histologic evidence of definite or probable NASH based upon a liver biopsy prior to
             enrollment and a NAFLD activity score (NAS) ≥5 with ≥1 in each component of the NAS
             score (steatosis, scored 0-3, ballooning degeneration, 0-2, and lobular inflammation,
             0-3).

          4. No past history of upper GI bleeding, ascites, hepatic encephalopathy

        Exclusion Criteria:

          1. Diagnosis of liver disease other than NASH cirrhosis

          2. History of gastrointestinal bleeding, ascites, hepatic encephalopathy

          3. Ongoing bacterial infection requiring antibiotic treatment.

          4. Current or history of significant alcohol consumption for a period of more than 3
             consecutive months within 1 year prior to screening

          5. Treatment with antibiotics or probiotics in the preceding 3 months.

          6. Inability to safely obtain a liver biopsy or perform an upper GI endoscopy

          7. Psychiatric disorder

          8. HIV

          9. Pregnant women

         10. Patients on SBP (Spontaneous Bacterial Peritonitis) prophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Abhinav Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Abhinav Verma, MD</last_name>
    <phone>011-46300000</phone>
    <email>abhinav.3183@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

